|
Treatment
|
Presence
|
Absence
|
Df
|
P value
|
|---|
|
cADV#
| | |
1
|
0.017b
|
|
C
|
81(89.0%)
|
10(11.0%)
|
|
F
|
19(67.9%)
|
9(32.1%)
|
|
rADV
| | |
1
|
0.001b
|
|
C
|
4(4.4%)
|
87(95.6%)
|
|
F
|
8(28.6%)
|
20(71.4%)
|
|
ETV
| | |
1
|
0.060a
|
|
C
|
51(56.0%)
|
40(44.0%)
|
|
F
|
10(35.7%)
|
18(64.3%)
|
|
Phos.
| | |
1
|
0.210a
|
|
C
|
53(58.2%)
|
38(41.8%)
|
|
F
|
20(71.4%)
|
8(28.6%)
|
|
Calcium
| | |
1
|
0.001a
|
|
C
|
47(51.6%)
|
44(48.4%)
|
|
F
|
3 (10.7%)
|
25(89.3%)
|
|
Calcitriol
| | |
1
|
0.185a
|
|
C
|
52(57.1%)
|
39(42.9%)
|
|
F
|
12(42.9%)
|
16(57.1%)
|
|
BM
| | |
1
|
0.755b
|
|
C
|
6(6.6%)
|
85(93.4%)
|
|
F
|
3(10.7%)
|
25(89.3%)
|
- *Ninety-one and 28 patients had treatment in the C and F group, respectively
- cADV ceased Adefovir Dipivoxil, rADV reduced Adefovir Dipivoxil, ETV entecavir, Phos. Phosphate supplement, Calcium Calcium supplement, Calcitriol Calcitriol supplement, BM drugs regulating bone metabolism
-
a
Pearson Chi-square test
- bCorrected Pearson Chi-square test
